Laflunimus

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameLaflunimus
Drug Alias NameHR-325AP-325
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor modulatorsDihydroorotate dehydrogenase inhibitors
TargetsDihydroorotate dehydrogenaseGamma-aminobutyric acid A receptor
Therapy Area/IndicationsNeuralgia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumGermany +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesAlgiax Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsNeuralgia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A